In any case, the bill allows the National Institutes of Health (NIH) to work with other agencies such as the Centers for Disease Control and Prevention (CDC) and the Substance Abuse Mental Health Department (SAMHSA) to "national cannabis is important. Develop a research agenda that addresses the gap between questions and evidence. ”
This agenda should include six key research goals. For example, regulators prioritize studies on the safety and efficacy of cannabis in the treatment of multiple symptoms, including epilepsy, multiple sclerosis, chemotherapy-related pain and nausea, and the use of marijuana as an alternative to opioids. is needed. Other items on the
agenda include the effects of cannabis on "risk groups" such as children and pregnant women, the "non-therapeutic effect" of marijuana, the relationship between cannabis use and behavioral health, and "clinically appropriate doses and Management route ". "Cannabis" and other public security considerations related to potency, youth access and abuse.
By law, federal agencies will also be required to work together to "perform surveillance activities to collect population-wide data on cannabis use."
data will be collected on health outcomes, demographics, product types, dosing regimens, and "other relevant health information to better understand cannabis use across age groups and subpopulations."
In addition, the bill requires editing of data from "public health surveillance systems, surveys, questionnaires, and medical record databases," such as the federal-funded "Future Surveillance" health survey.
This section is accompanied by a privacy statement requiring data collection in a manner that "protects privacy at least to the extent required by applicable federal and state law." Section 3 of the
Law tells the NIH Director that certain universities are "Cannabis Research Center of Excellence for the purpose of interdisciplinary research related to cannabis and other biomedical, behavioral, and social issues related to cannabis." Requests to be specified as.
Educational institutions interested in receiving this designation can submit an application to NIH to train students and professionals on research capabilities, disciplines, staff, the ability to coordinate research across institutions, and marijuana-related issues. You must state your qualifications to manage the academic course to do so. chance.
"When choosing a university to be designated as the Center of Excellence in Cannabis Research, the NIH Director shall prioritize institutions with a proven track record in medical cannabis research," the policy said. The designation is valid for 5 years, after which the institution can reapply. The
NIH has the authority to grant grants or enter into collaborative research agreements with up to 10 cannabis research centers and can allocate $ 50 million for each fiscal year from 2024 to 2028.
"The Director of NIH shall promptly communicate the results of research under this subsection to relevant governments, academics, and research institutes," the bill said.
Finally, the bill contains a section designed to streamline the registration process for university researchers interested in conducting cannabis research. The designated Center of Excellence in cannabis research is also protected from federal sanctions when procuring marijuana from state pharmacies for research purposes.
The bill is similar to the measures introduced by Senator Dick Durbin (D-IL) in 2019 and the ancillary measures introduced by some members this year, with one important difference being earlier. The law moves marijuana from Schedule I to Schedule III under the Controlled Substances Act (CSA). His exclusion is probably the recognition that many supporters of cannabis legalization now believe that it is an inadequate reform compared to removing the plant completely from the CSA.
The submission of this latest bill passes another bipartisan marijuana research bill aimed at facilitating and simplifying the process by which the U.S. House of Representatives obtains approval to study the risks and benefits of marijuana. It happens in the same week that you voted for it individually. This measure, which does not allow researchers to study dispensing cannabis, is expected to be taken up by the Senate, perhaps shortly before being sent to the president's desk.